Lars Jacobsson Selected Research

Radioimmunotherapy

1/2023	Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy.
1/2019	Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
12/2017	Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.
4/2016	Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors.
1/2015	Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
7/2009	Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
11/2006	Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
11/2006	Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
8/2006	Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
12/2005	211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Jacobsson Research Topics

Disease

24	Neoplasms (Cancer) 01/2024 - 05/2002
16	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 09/2003
5	Ascites 12/2017 - 11/2005
3	Carcinoma (Carcinomatosis) 08/2013 - 10/2007
2	Ovarian Epithelial Carcinoma 01/2023 - 01/2019
2	Neoplasm Micrometastasis 08/2013 - 09/2003
2	Schizophrenia (Dementia Praecox) 06/2013 - 04/2012
1	Intestinal Perforation 01/2019
1	Fatigue 01/2019
1	Body Weight (Weight, Body) 12/2017
1	Residual Neoplasm 11/2015
1	Tardive Dyskinesia 02/2015
1	Disease Progression 03/2013

Drug/Important Bio-Agent (IBA)

9	Monoclonal AntibodiesIBA 01/2019 - 03/2003
6	211At-labeled monoclonal antibody MX35IBA 01/2021 - 08/2006
3	AntibodiesIBA 01/2021 - 09/2003
3	Radioisotopes (Radionuclides)IBA 01/2018 - 06/2003
3	Antipsychotic Agents (Antipsychotics)IBA 02/2015 - 04/2012
2	Astatine-211IBA 01/2021 - 10/2007
2	EpitopesIBA 01/2015 - 09/2003
2	Immunoconjugates (Immunoconjugate)IBA 08/2013 - 12/2005
2	Lysine (L-Lysine)FDA Link 12/2011 - 05/2002
2	AstatineIBA 12/2009 - 09/2003
1	SolutionsIBA 01/2024
1	Contrast MediaIBA 01/2023
1	Colloids (Colloid)IBA 01/2023
1	Thorium Dioxide (Thorotrast)IBA 01/2023
1	Rituximab (Mabthera)FDA Link 01/2021
1	farletuzumabIBA 01/2021
1	AntigensIBA 01/2019
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2015
1	Hematoxylin (Haematoxylon)IBA 08/2013
1	Eosine Yellowish-(YS) (Eosin)IBA 08/2013
1	procaine isothiocyanate (PRIT)IBA 03/2013
1	AvidinIBA 12/2011
1	Dihydrotachysterol (AT 10)IBA 10/2010
1	Trastuzumab (Herceptin)FDA Link 10/2007
1	poly-d-lysineIBA 09/2003
1	Biotin (Vitamin H)FDA Link 09/2003
1	SuspensionsIBA 03/2003

Therapy/Procedure

13	Radioimmunotherapy 01/2023 - 09/2003
12	Therapeutics 01/2023 - 05/2002
4	Drug Therapy (Chemotherapy) 01/2023 - 07/2009
4	Aftercare (After-Treatment) 12/2017 - 11/2005
2	Catheters 01/2019 - 07/2009
1	Intravenous Injections 01/2021
1	Transcutaneous Electric Nerve Stimulation (TENS) 08/2013
1	Radiotherapy 10/2010